Exagen Stock Price, News & Analysis (NASDAQ:XGN) $1.86 +0.05 (+2.76%) (As of 01:37 PM ET) Add Compare Share Share Today's Range$1.79▼$1.9350-Day Range$1.45▼$2.5352-Week Range$1.33▼$3.92Volume11,255 shsAverage Volume20,478 shsMarket Capitalization$31.71 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Exagen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside200.5% Upside$5.50 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$59,183 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.46) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector79th out of 949 stocksMedical Laboratories Industry2nd out of 21 stocks 3.5 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Exagen has a forecasted upside of 200.5% from its current price of $1.83.Amount of Analyst CoverageExagen has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.09% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently increased by 4.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for XGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,183.00 in company stock.Percentage Held by Insiders36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.85% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.46) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exagen Stock (NASDAQ:XGN)Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More XGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XGN Stock News HeadlinesNovember 17, 2023 | msn.comExagen files for a $150M mixed shelf offeringNovember 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 13, 2023 | msn.comExagen GAAP EPS of -$0.31 beats by $0.15, revenue of $13.4M beats by $3.07MNovember 13, 2023 | finance.yahoo.comExagen Inc. Reports Strong Third Quarter 2023 ResultsNovember 12, 2023 | markets.businessinsider.comHere's what to expect from Exagen's earnings reportNovember 10, 2023 | benzinga.comEarnings Preview For ExagenNovember 9, 2023 | msn.comExagen licenses lupus nephritis biomarkers from Johns HopkinsDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 9, 2023 | finance.yahoo.comExagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis BiomarkersNovember 2, 2023 | finance.yahoo.comExagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNovember 1, 2023 | morningstar.comExagen Inc Ordinary Shares XGNOctober 30, 2023 | finance.yahoo.comExagen to Announce Third Quarter 2023 Financial Results on November 13, 2023September 28, 2023 | finance.yahoo.comExagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual MeetingSeptember 12, 2023 | finance.yahoo.comExagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceAugust 9, 2023 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call TranscriptAugust 7, 2023 | msn.comExagen beats Q2 top and bottom line estimates; initiates Q3 outlookAugust 7, 2023 | finance.yahoo.comExagen Inc. Reports Strong Second Quarter 2023 ResultsAugust 4, 2023 | benzinga.comExagen's Earnings OutlookJuly 26, 2023 | finance.yahoo.comExagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJuly 25, 2023 | finance.yahoo.comExagen to Announce Second Quarter 2023 Financial Results on August 7, 2023July 24, 2023 | finance.yahoo.comExagen Inc. Appoints Paul Kim to Board of DirectorsJuly 24, 2023 | finance.yahoo.comThis Exagen Insider Increased Their Holding In The Last YearJune 13, 2023 | finance.yahoo.comExagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For ExcitementMay 30, 2023 | finance.yahoo.comExagen Inc. to Participate in the William Blair 43rd Annual Growth Stock ConferenceMay 17, 2023 | finance.yahoo.comExagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three yearsMay 16, 2023 | msn.comCantor Fitzgerald Reiterates Exagen (XGN) Overweight RecommendationSee More Headlines Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees199Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$6.00 Low Stock Price Target$5.00 Potential Upside/Downside+200.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,390,000.00 Net Margins-62.90% Pretax Margin-63.45% Return on Equity-81.62% Return on Assets-38.71% Debt Debt-to-Equity Ratio0.70 Current Ratio4.83 Quick Ratio4.83 Sales & Book Value Annual Sales$45.56 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.70Miscellaneous Outstanding Shares17,050,000Free Float10,773,000Market Cap$31.20 million OptionableNot Optionable Beta1.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Tina S. Nova Ph.D. (Age 69)Executive Chairman of Board Comp: $65kMr. John Aballi (Age 38)CEO, President & Director Comp: $558.84kMr. Kamal Adawi M.S. (Age 44)MBA, CFO & Corporate Secretary Comp: $483.28kMr. Mark Hazeltine (Age 49)Chief Business Officer Comp: $483.28kRyan DouglasInvestors Relations OfficerMr. John Wegener (Age 54)Senior Vice President of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardDr. Michael I. Nerenberg M.D. (Age 68)Chief Medical Officer More ExecutivesKey CompetitorsAkuminNASDAQ:AKUAkuminNASDAQ:AKUMQCentogeneNASDAQ:CNTGPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCBought 154,139 shares on 11/14/2023Ownership: 7.138%John AballiSold 33,819 sharesTotal: $59,183.25 ($1.75/share)James L L TullisBought 167 shares on 6/15/2023Total: $519.37 ($3.11/share)Mark HazeltineSold 5,821 sharesTotal: $15,658.49 ($2.69/share)John AballiBought 90,000 shares on 12/8/2022Total: $241,200.00 ($2.68/share)View All Insider TransactionsView All Institutional Transactions XGN Stock Analysis - Frequently Asked Questions Should I buy or sell Exagen stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks. What is Exagen's stock price target for 2024? 3 brokers have issued 1-year price targets for Exagen's shares. Their XGN share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 200.5% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts. How have XGN shares performed in 2023? Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has decreased by 23.8% and is now trading at $1.83. View the best growth stocks for 2023 here. When is Exagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our XGN earnings forecast. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) announced its earnings results on Wednesday, November, 10th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.04. The company earned $12.25 million during the quarter, compared to analysts' expectations of $12.13 million. Exagen had a negative trailing twelve-month return on equity of 81.62% and a negative net margin of 62.90%. During the same period in the prior year, the company earned ($0.34) EPS. What guidance has Exagen issued on next quarter's earnings? Exagen issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50.00M-, compared to the consensus revenue estimate of $46.76 million. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO. Who are Exagen's major shareholders? Exagen's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis, John Aballi, Mark Hazeltine, Nmsic Co-Investment Fund, LP and Wendy S Johnson. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:XGN) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.